Chronic Kidney Disease (CKD) as a systemic disease: Whole body autoregulation and inter-organ cross-talk

Kidney and Blood Pressure Research

Volumn 39, Issue 2-3, 2014, Pages 134-141

  Zoccali, Carmine ^a   Tripepi, Giovanni ^a   Dounousi, Evangelia ^b   Mallamaci, Francesca ^a,c  

^a CNR   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Neonatal Intensive Care Unit Ospedali Riuniti Reggio Calabria   (Italy)

Author keywords

ADMA; Cardiovascular; CKD; ESRD; FGF23; NPY; Phenotype; Progression; Risk; Sympathetic

Indexed keywords

DIMETHYLARGININASE; FIBROBLAST GROWTH FACTOR 23; N(G),N(G) DIMETHYLARGININE;

AUTOREGULATION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; END STAGE RENAL DISEASE; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; PATHOPHYSIOLOGY; PRESSORECEPTOR; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; SYSTEMIC DISEASE; UNINEPHRECTOMY; CHRONIC KIDNEY FAILURE;

HOMEOSTASIS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84906028593     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355788     Document Type: Review

References (36)

1. Atzler D, Schwedhelm E, Zeller T: Integrated genomics and metabolomics in nephrology. Nephrol Dial Transplant 2013, DOI 10.1093/ndt/gft492.
2. Guyton AC: Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989;2:575-585.
3. DiBona GF, Sawin LL: Renal nerve activity in conscious rats during volume expansion and depletion. Am J Physiol 1985;248:F15-F23.
4. Baldock P.A. Lee NJ Driessler F Lin S Allison S Stehrer B Lin EJ Zhang L Enriquez RF Wong IP McDonald MM During M Pierroz DD Slack K Shi YC Yulyaningsih E Aljanova A Little DG Ferrari SL Sainsbury A Eisman JA, Herzog H Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 2009 4 e8415.
5. Lohmeier TE, Mizelle HL, Reinhart GA: Role of atrial natriuretic peptide in long-term volume homeostasis. Clin Exp Pharmacol Physiol 1995;22:55-61.
6. O'Connor PM, Cowley AW, Jr: Modulation of pressure-natriuresis by renal medullary reactive oxygen species and nitric oxide. Curr Hypertens Rep 2010;12:86-92.
7. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-G ayk H, Haller H, Fliser D: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004;27:143-147.
8. Heineke J , Kempf T, Kraft T, Hilfiker A, Morawietz H, Scheubel RJ, Caroni P, Lohmann SM, Drexler H, Wollert KC: Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation 2003;107:1424-1432.
9. Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD: The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide 2011;25:41-46.
10. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-345.
11. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Tager M, Bode-Boger SM: Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 2004;24:1816-1822.
12. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-3828.
13. Quarles LD: Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012;8:276-286.
14. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John SM, Ojo A, Gadegbeku C, Di Marco GS, Reute r S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro O, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
15. G rassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'oro R, Mancia G: Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011;57:846-851.
16. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, Zoccali C: Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2620-2627.
17. Converse RL, Jr., Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 19 92;327:1912-1918.
18. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, Van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by ena lapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-1328.
19. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Bohm M, Cremers B, Esler MD, Schlaich MP: Renal denervation in moderate to severe CKD. J Am Soc Nephrol 20 12;23:1250-1257.
20. Amann K, Hofstetter J, Campean V, Koch A, Gross ML, Veelken R, Ritz E: Nonhypotensive dose of betaadrenergic blocker ameliorates capillary deficits in the hearts of rats wi th moderate renal failure. Virchows Arch 2006;449:207-214.
21. Veelken R, Vogel EM, Hilgers K, Amann K, Hartner A, Sass G, Neuhuber W, Tiegs G: Autonomic renal denervation ameliora tes experimental glomerulonephritis. J Am Soc Nephrol 2008;19:1371-1378.
22. Panuccio V, Cutrupi S, Pizzini P, Mallamaci F, Tripepi G, Zoccali C: Neuropeptide Y and markers of osteoblast a ctivity in dialysis patients: a cross-sectional study. Am J Kidney Dis 2007;50:1001-1008.
23. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Har ders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC, Jr: Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 2012;302:R292-R299.
24. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG: Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012;23:1725-1734.
25. Salvetti M Muiesan ML Paini A Monteduro C Bonzi B Galbassi ni G Belotti E Movilli E Cancarini G Agabiti-Rosei E Myocardial ultrasound tissue characterization in patients with chronic renal failure. J Am Soc Nephrol 2007 18 1953-1958.
26. Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, Fang W, Wang Q, Cao L, Yan Y, Qian J: Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 2010;21:444-448.
27. Mihout F, Shweke N, Bige N, Jouanneau C, Dussaule JC, Ronco P, Chatziantoniou C, Boff a JJ: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 2011;223:37-45.
28. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007;18:1525-1533.
29. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts p rogression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-2455.
30. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
31. Wang Z, Lambden S, Taylor V, Sujkovic E, Nandi M, Tomlinson J, Dyson A, McDonald N, Caddick S, Singer M, Leiper J: Pharmacological inhibition of DDAH1 improves survival, hemodynamics and organ function in experimental septic shock. Biochem J 2014;460:309-316.
32. Zoccali C, Leonardis D, Tripepi G, Enia G, Mallamaci F: FGF23 and Asymmetrical Dimethylarginine (ADMA) Are Interactive Factors in the High Risk for CKD Progression in Stage 2-5 CKD Patients. J Am Soc Nephrol 2012;23:175A.
33. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, Matsumura Y, Masuda H, Kurabayashi M, Kuro-o M, Nabeshima Y, Nagai R: Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998;248:324-329.
34. Nakamura T, Saito Y, Ohyama Y, Masuda H, Sumino H, Kuro-o M, Nabeshima Y, Nagai R, Kurabayashi M: Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002;89:149-156.
35. Zoccali C, Goldsmith D, Agarwal R, Blankestijn PJ, Fliser D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Covic A, Martinez-Castelao A, Jager KJ, Dekker FW, Lindholm B, London G: The complexity of the cardio-renal link: taxonomy, syndromes and diseases. Kidney Int Suppl 2011;1:2-5.
36. Cozzolino M, Ureñ a-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S: Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transp lant 2014, DOI 10.1093/ndt/gft514.